BOXED WARNING Increased mortality in elderly patients with dementia-related psychosis treated with antipsychotics; not approved for dementia-related psychosis.
FDA dosing
Population
Start
Target
Max
Schizophrenia (milder)
Adults
2 mg TID
15 mg/day
60 mg/day
Schizophrenia (more severe)
Adults
5 mg BID
20-30 mg/day
60 mg/day
Renal Undefined
Hepatic Undefined
Exceeding 60 mg/day rarely increases benefit
Instructions
Individualize dose; start small and increase gradually to optimal effect
Some patients maintained on once-daily dosing
Not recommended in children under 12 years
Available strengths
cap 1, 2, 5, 10 mg
Contraindications
Circulatory collapse
Comatose states or CNS depression due to any cause
Blood dyscrasias
Cautions
Tardive dyskinesia with long-term use
Neuroleptic malignant syndrome (NMS)
Extrapyramidal symptoms and dystonia, especially early and at higher doses
Orthostatic hypotension/syncope (do not use epinephrine as pressor)